<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879761</url>
  </required_header>
  <id_info>
    <org_study_id>13-0491</org_study_id>
    <nct_id>NCT01879761</nct_id>
  </id_info>
  <brief_title>Immune Resolution After Staphylococcus Aureus Bacteremia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how monocyte HLA-DR and other markers of immune
      function change with time in patients with and without prior immune dysfunction who survive
      sepsis from Staphylococcus aureus bacteremia.

      We hypothesize that patients with prior immune dysfunction will have greater reductions in
      HLA-DR and other markers of immune function after an episode of sepsis than people who do not
      have prior immune dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HLA-DR and cytokines</measure>
    <time_frame>0-30 days</time_frame>
    <description>Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Infections</measure>
    <time_frame>0-90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>0-90 days</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Immune Response To Sepsis</condition>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Immunosuppressed</arm_group_label>
    <description>Immunosuppressed includes patients with any one of the following:
a diagnosis of a hematological malignancy
a diagnosis of HIV
myelosuppressive chemotherapy in the previous 90 days
immune-modulating medications in the previous 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Immunosuppressed</arm_group_label>
    <description>Subject does not fit immunosuppressed criteria</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Isolated monocytes from whole blood for HLA-DR measurement. Serum and plasma for cytokine
      measurements
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one blood culture positive for S. aureus

          -  Patients aged ≥18 years

          -  At least two of four systemic inflammatory response syndrome (SIRS) criteria on the
             day of positive blood cultures. SIRS criteria are:

               -  Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)

               -  Heart rate greater than 90 beats per minute

               -  Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or,
                  an arterial partial pressure of carbon dioxide less than 32 mmHg

               -  WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³
                  (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils
                  (band forms)

        Exclusion Criteria:

          -  Sequential Organ Failure Assessment (SOFA) score &gt; 12 on day of positive blood
             cultures

          -  Survival expected to be &lt; 7 days from positive blood cultures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Pohlman, RN</last_name>
      <phone>773-702-3804</phone>
      <email>apohlman@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>John Kress, MD</last_name>
      <phone>773-702-1000</phone>
      <email>jkress@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jared A Greenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Kress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne I Sperling, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert S Daum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Z David, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhakti K Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne S Pohlman, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phil Verhoef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppressed</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>HLA-DR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

